Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.

Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Tags: , , , , ,

Related Post

Redenlab partners with BDCRC to support new NIH-funded Batten disease research

  • Posted on 19 November, 2025
    MEDIA RELEASE MELBOURNE, VIC - A newly formed research network focused on Batten disease, a rare and inherited brain disorder...
    Read more

    Examination of speech processing in noise reveals cognitive deficits in early Huntington’s disease 

    • Posted on 7 October, 2025
      Struggling to follow a conversation in noise could be more than just annoying, it might signal early cognitive issues in...
      Read more

      Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia

      • Posted on 25 July, 2025
        A new clinical trial has found early evidence that a metabolic therapy could improve outcomes for people with ataxia-telangiectasia (A-T),...
        Read more